This was one of the busiest weeks in peptide news in recent memory. Between a landmark FDA advisory vote, blockbuster weight-loss trial results, and a full-blown advertising war between the two biggest names in GLP-1 medications, here is what actually happened and what it means for you, without the hype.
What Did the FDA Decide About BPC-157 and Other Peptides This Week?
On July 23 and 24, the FDA's Pharmacy Compounding Advisory Committee voted to recommend that six peptides, including BPC-157 (the so-called "recovery peptide"), along with KPV, MOTS-c, TB-500, Epitalon, and Semax, be added back to the list of substances licensed compounding pharmacies can legally prepare with a prescription. A seventh, Emideltide, was rejected.
Two things are important to understand before anyone celebrates or panics.
First, nothing is legal yet. The committee's votes are recommendations. The FDA still has to decide whether to accept them, and there is no set timeline. Compounded BPC-157 remains off the market today.
Second, the science has not changed, only the vote did. The FDA's own scientific reviewers concluded the evidence for these peptides was insufficient, noting that several have never been studied for safety in humans at all. The advisory panel voted in favor anyway. That gap between enthusiasm and evidence is exactly where patients deserve honest guidance.
"Regulated access is not the same as proven benefit. Anyone considering peptide therapy should be having that conversation with a clinician who knows their full health picture, not a checkout page." — Amsara Health editorial team
If the FDA finalizes these recommendations, it would move peptides like BPC-157 out of the gray market and into regulated pharmacies with prescriber oversight, which would be a genuine safety improvement over unregulated "research use only" vials.
What Is Retatrutide, and Is It Really Better Than Ozempic or Zepbound?
Eli Lilly announced this week that Retatrutide, a "triple agonist" peptide that targets three metabolic hormone receptors instead of one or two, succeeded in two more Phase 3 trials. In adults with severe obesity and established cardiovascular disease, average weight loss reached 22.6% of body weight (about 56 pounds) at 80 weeks, the strongest results seen from any medication in this class. In adults with type 2 diabetes, higher doses produced roughly 19 to 21% weight loss with meaningful A1C reductions.
Before you ask your provider for it: Retatrutide is not available yet. Lilly plans to file with the FDA in early 2027, which realistically means approval in 2027 to 2028. And a caution worth repeating: any "Retatrutide" being sold online today is unapproved, illegal to compound, and untested for quality. If you see it for sale, walk away.
The right medication is the one that fits your health, your goals, and your life today. Semaglutide and Tirzepatide remain the well-studied, FDA-approved options, and waiting years for a stronger drug is rarely the right plan when proven tools exist now.
Is There a GLP-1 Pill Instead of Injections?
Yes, and that story keeps growing. This week the European Union approved the Wegovy pill (oral Semaglutide) for weight management, the first oral GLP-1 for obesity in Europe. In the U.S., where the pill launched earlier this year, prescriptions have already passed three million.
For the many patients who have put off treatment because of needle anxiety, the needle-free era has genuinely arrived, with oral Semaglutide and oral Orforglipron now in the mix alongside weekly injections. Each option has different strengths, dosing routines, and food-timing rules, which is exactly the kind of decision a 15-minute conversation with a midlife-focused clinician can simplify.
Meanwhile, the competition is getting noisy: Novo Nordisk filed legal action this week to stop Eli Lilly's head-to-head advertising claims. When drugmakers are suing each other over ads, it is a good reminder that your treatment decision should come from your clinician and your labs, not a commercial.
What Should Women in Midlife Know Before Starting a GLP-1 or Peptide?
This is the question we care about most at Amsara Health, and it is the part the headlines keep skipping.
Midlife changes the math. During and after the menopause transition, women naturally lose muscle and bone density at an accelerated rate, and rapid weight loss from any cause can compound both. Researchers are actively studying this right now: a dedicated clinical trial on GLP-1 effects on lean mass and bone health in midlife women is underway (ClinicalTrials.gov NCT07422987), and early studies suggest bone density deserves real attention in higher-risk women using these medications.
None of this means midlife women should not use GLP-1s. For many, the metabolic benefits are life-changing. It means the how matters:
- Protein and strength training are not optional. They are part of the prescription.
- Bone health should be assessed, not assumed, especially post-menopause.
- Hormones, sleep, and weight are connected systems. Treating one without looking at the others is how women end up feeling worse while weighing less.
- Source matters. Independent testing has found heavy metals in some gray-market peptides sold online. Prescription products from licensed U.S. pharmacies, with clinician oversight, are the only version of this worth doing.
Frequently Asked Questions
Is BPC-157 legal now?
No. An FDA advisory committee voted this week to recommend allowing licensed pharmacies to compound it, but the FDA has not yet accepted the recommendation. Until it does, compounded BPC-157 remains unavailable through legitimate channels.
Are peptides the same thing as GLP-1 medications?
GLP-1 medications like semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) are peptides, specifically rigorously tested, FDA-approved ones. The peptides in this week's FDA vote (BPC-157, TB-500, and others) are a different group with far less human evidence behind them.
Should I wait for retatrutide instead of starting treatment now?
For most people, no. Retatrutide's results are impressive, but approval is likely one to two years away. FDA-approved options available today are effective and well-studied, and your health does not benefit from waiting.
How do I know if peptide or GLP-1 therapy is right for me in midlife?
Amsara Health has practitioners who specialize in midlife health and will look at the whole picture: your labs, hormones, bone and muscle health, medications, and goals. That is the difference between a prescription and a plan. See if we have someone in your practice area by clicking here.
Sources
- STAT News. FDA panel backs compounding of BPC-157, KPV, MOTS-c, TB-500 (July 23, 2026)
- STAT News. Panel backs Epitalon and Semax, rejects emideltide (July 24, 2026)
- FDA. Pharmacy Compounding Advisory Committee meeting, July 23 to 24, 2026
- Washington Post. FDA panel gives nod to six controversial peptides (July 24, 2026)
- Eli Lilly. Retatrutide TRIUMPH-2 and TRIUMPH-3 topline results (July 23, 2026)
- Fierce Biotech. Retatrutide hits 22.6% weight loss (July 2026)
- Novo Nordisk. EU approval of Wegovy pill (July 15, 2026)
- Novo Nordisk. Action against misleading GLP-1 advertising (July 21, 2026)
- Forbes. Companies preparing to sell compounded peptides (July 22, 2026)
- ClinicalTrials.gov. GLP-1RA Effects on Lean Mass and Bone Health in Midlife Women (NCT07422987)
- UCHealth. Menopause, GLP-1s, and bone loss
The information in this article is for educational purposes only and is not medical advice. Always consult a licensed healthcare provider about your individual situation before starting, stopping, or changing any treatment.